Why Winnow uses raw potato starch

Most people scan a supplement label looking for the ingredients that seem to do the obvious work: the probiotic strains, the CFU count, the parts that sound active.

Then they see “raw potato starch” and move on.

At first glance, it reads like filler. Something neutral that is there because capsules need bulk.

That reaction is understandable. It is also incomplete.

The starch in Winnow was not chosen at random. It was chosen because probiotics do not function in isolation. They arrive in an ecosystem shaped by substrate, competition, fermentation, and timing. The material surrounding those organisms as they move through the gut is not irrelevant. It can influence whether they survive, how they behave, and what metabolites are ultimately produced.

This piece explains what resistant starch is, why it matters to probiotic function, what the human research actually shows at different doses, and why we are careful about where Winnow’s formulation does and does not overlap with that literature.

What resistant starch is, and why most starch is not

Starch is a glucose polymer. In ordinary foods like bread, rice, or pasta, digestive enzymes begin breaking that starch down almost immediately. By the time it moves through the small intestine, much of it has been converted into glucose and absorbed. The colon sees very little of it.

Resistant starch is different. It resists digestion in the upper gastrointestinal tract and arrives in the large intestine largely intact ^[1-2]. There, it becomes substrate for gut bacteria rather than fuel directly absorbed by the host. That distinction matters because the colon is where most of the microbiome lives, and what reaches it helps determine what that microbial community can do.

Resistant starch (RS) is typically grouped into five types, based on why it resists digestion ^[1-3]:

• RS1: Starch physically trapped inside intact plant cell walls, as in some whole grains and legumes
• RS2: Native granular starch with a tightly packed crystalline structure that limits enzyme access, found in raw potatoes, green bananas, and high amylose maize
• RS3: Retrograded starch formed when cooked starch cools and its chains realign into a more digestion resistant structure
• RS4: Chemically modified starches designed for industrial applications
• RS5: Starch lipid complexes

Raw potato starch is predominantly RS2. Its granules are large and relatively smooth, with fewer accessible surface features than many cereal starches, making them harder for enzymes to penetrate ^[4]. Its crystalline structure is also important. Potato starch is rich in B type crystallinity, which is inherently more resistant to enzymatic hydrolysis than the A type pattern more common in wheat and corn ^[4-5].

Cooking changes that. Heat gelatinizes the granules, disrupting the structure that gives RS2 its resistance and making the starch far more digestible. A raw potato may contain roughly 60 to 80% resistant starch by dry weight, while a cooked potato may drop to only 2 to 4% ^[1,6]. If the goal is RS2, the starch has to remain uncooked.

What happens when resistant starch reaches the colon

The colon is not simply a storage site. It is a dense microbial environment where bacteria compete for available substrate, and the substrates that arrive there influence which metabolic pathways are favored.

Resistant starch is fermented by colonic anaerobes into short chain fatty acids, primarily acetate, propionate, and butyrate ^[2,7]. That is not a trivial downstream effect. Short chain fatty acids are one of the core ways the microbiome communicates with the host, and butyrate in particular has an outsized role in colonic physiology.

The degradation hierarchy

Not all bacteria can break down resistant starch directly. The process depends on species with the right enzymatic toolkit, including glycoside hydrolases and starch binding proteins that allow them to anchor to the starch granule and begin digesting it ^[7-8].

For potato derived RS2, the best known primary degraders include Bifidobacterium species and Ruminococcus bromii^[8-10]. These organisms begin the work, but they do not consume every product themselves. They release smaller carbohydrates, acetate, and lactate into the lumen, where secondary fermenters such as Faecalibacterium prausnitzii and Eubacterium rectale can convert them into butyrate ^[7-8].

This is cross feeding. It is one of the clearest examples of how a healthy gut ecosystem functions collectively rather than individually. Primary degraders open the substrate. Secondary fermenters turn those breakdown products into metabolites that matter to the host. The system depends on both the right organisms and the right food source arriving together.

Why butyrate matters

Butyrate is the preferred fuel source for colonocytes, supplying a substantial share of their energy needs ^[2-7]. It also appears to support barrier function, reduce inflammatory signaling, and influence gene expression through histone deacetylase inhibition ^[7,11-12].

Those mechanisms are well described in preclinical work. The translation into broad, consistent systemic clinical outcomes in humans is less settled. That distinction matters, and we will come back to it.

Individual variability is real

One of the most important features of the resistant starch literature is that not everyone responds the same way.

In one controlled study of twenty healthy adults given unmodified potato starch, escalated to roughly 24 grams per day of resistant starch over seven days, fecal butyrate increased at the group level. But the response was not uniform. Some participants showed clear increases in RS degrading organisms and butyrate production, while others showed much smaller changes ^[9].

Subsequent work has suggested that baseline microbiome composition, particularly the presence or absence of organisms such as R. bromii and certain Bifidobacterium species, helps determine whether a person responds meaningfully to resistant starch supplementation ^[9-10,13].

That is a useful corrective to simplistic prebiotic language. Resistant starch is not a universal switch. It is a substrate whose effect depends on the ecology it enters.

What the clinical evidence shows

The clinical literature on resistant starch is broad. It touches microbiome composition, short chain fatty acid production, bowel function, glycemic control, lipid metabolism, inflammatory signaling, and body composition. But the strength of evidence varies by endpoint, and the consistency is not the same across categories.

Microbiome shifts

This is one of the strongest parts of the literature.

In a randomized, placebo controlled trial of 75 healthy adults, doses of 3.5 grams per day and 7 grams per day of unmodified resistant potato starch for four weeks significantly increased the relative abundance of Bifidobacterium and Akkermansia compared with placebo ^[14]. Both doses also improved certain stool related outcomes, including a reduction in liquid bowel movements and constipation associated stool patterns ^[14-15]. Secondary analyses linked some of these shifts to improvements in bowel symptoms and identified microbiome changes that correlated with lower LDL cholesterol ^[15-16].

At higher doses, the pattern becomes more pronounced. In the seven day potato starch study mentioned earlier, approximately 24 grams per day of resistant starch increased fecal butyrate at the group level, especially in participants whose microbiomes already contained the organisms best equipped to metabolize it ^[9]. In elderly adults, 30 grams per day of resistant potato starch over twelve weeks increased Bifidobacterium and Akkermansia while reducing E. coli and broader Proteobacteria levels ^[17].

These are meaningful human findings. Resistant potato starch can shift the microbiome at relatively modest doses, and the direction of those shifts is generally consistent with what the field would consider favorable.

Glycemic and metabolic endpoints

This part of the literature is more mixed.

A meta analysis of thirteen controlled studies involving 428 participants found that resistant starch supplementation improved fasting insulin, fasting glucose, and HOMA IR in overweight and obese adults, with larger effects at higher doses and longer durations ^[18]. In elderly adults, 30 grams per day improved fasting glucose, insulin, and HOMA IR, though similar changes were not seen in the middle aged subgroup of the same trial ^[17].

A tightly controlled crossover trial using 40 grams per day of RS2 over eight weeks reported reductions in body weight, abdominal adiposity, and insulin resistance, alongside microbiome and bile acid changes that may help explain those effects ^[19]. But another twelve week crossover study using the same dose in adults with well controlled type 2 diabetes found improvements in postprandial glucose and GLP 1 dynamics without improvement in clamp measured insulin sensitivity or HbA1c, and fasting triglycerides increased ^[20].

The most honest summary is that metabolic benefits are plausible, and in some populations they appear clinically relevant. But they are also dose dependent, population dependent, and not consistently reproduced across every endpoint.

Inflammation

There is also signal here, but again with limits.

Meta analyses of randomized trials suggest that resistant starch can reduce certain inflammatory markers, particularly TNF-alpha and IL-6, with stronger effects generally seen at doses above 20 grams per day ^[21]. At the same time, pooled analyses do not consistently show significant effects on C reactive protein ^[21].

Mechanistically, the pathway is believable. Butyrate can suppress NF-κB related signaling and influence immune regulation. That is well supported in cell and animal work ^[12,21]. But moving from local colonic biology to consistent systemic anti-inflammatory effects in humans is not straightforward.

Separating the evidence layers

This is where nuance matters.

Some findings are reasonably well established in humans. Others remain promising but variable. Others are still mainly mechanistic.

• Established in humans: Resistant starch can shift microbiome composition toward taxa such as Bifidobacterium and Akkermansia. In responders, it can increase fecal short chain fatty acid production. Detectable prebiotic effects have been observed at doses as low as 3.5 grams per day ^[14].
• Supported but heterogeneous in humans: Glycemic improvements, especially at higher doses and in metabolically impaired populations ^[18-20]. Reductions in certain inflammatory cytokines ^[21].
• Mechanistically plausible but not firmly established in humans: Direct improvement of gut barrier integrity, epigenetic effects relevant to cancer prevention, and broader systemic benefits inferred from butyrate biology ^[11-12,22].

This layering matters because it is easy for a field like this to blur together what is known, what is plausible, and what is simply being extrapolated.

The dose question, and why we are direct about it

This is the part many supplement brands would likely pass over quickly.

Winnow contains approximately 0.5 grams of raw potato starch per daily serving. That corresponds to roughly 0.3 to 0.4 grams of resistant starch, assuming a typical RS2 content of about 60 to 80% in unmodified raw potato starch.

The clinical literature looks very different:

We are not going to suggest that 0.5 grams of raw potato starch reproduces the effects seen in trials using 3.5 to 40 grams per day. It does not. There is no published human study showing standalone health effects from sub-gram doses of resistant starch.

That is not the role the potato starch is playing in our formulation.

Why it is in the capsule anyway

The rationale is not that this amount constitutes a therapeutic resistant starch dose on its own. The rationale is that probiotic delivery is not only about which strains are present. It is also about the context in which they arrive.

Probiotics do not arrive into a vacuum

A probiotic capsule is a delivery system for living organisms. When those organisms reach the colon, they enter a crowded ecosystem where resident microbes already occupy most of the terrain. Even transient survival may depend in part on whether the incoming organisms have access to nearby substrate they can use ^[23-24].

This is part of the logic behind synbiotics, which pair probiotics with prebiotics. The prebiotic does not always need to reshape the entire microbiome by itself. In some formulations, its role is more local and immediate. It may provide a substrate advantage, or at least a more biologically sensible environment, during the critical window when the organisms arrive ^[23-25].

The evidence for co-delivery

Several lines of evidence support the broader principle that substrate matters when probiotics are delivered:

• Synbiotic superiority: In a mouse model of inflammatory bowel disease, green banana resistant starch combined with Bacillus coagulans spores reduced disease activity and tissue damage more than either component alone, with higher SCFA production and lower inflammatory burden ^[26].
• Complementary substrate effects: The broader synbiotic literature suggests that pairing probiotics or other beneficial microbes with fermentable substrates can create more favorable microbial conditions than delivering either in isolation, though the effect likely varies with the substrate, the dose, and the host ecology ^[23,25,27].
• Survival under stress: Potato derived fiber has been shown to improve the survival of certain Lactobacillus species under simulated gastric conditions ^[28]. When potato starch was used in co-encapsulation systems with alginate, probiotic viability and encapsulation efficiency improved ^[28].
• Aging related inflammation: Reviews of resistant starch, probiotics, and resistant proteins in older adults suggest that the combination may influence gut microbial metabolism and inflammatory processes through overlapping but distinct mechanisms ^[29].

None of these studies used Winnow’s exact formula, and none were conducted at a 0.5 gram potato starch dose. But they do support an important formulation principle: the material paired with a probiotic is not always incidental. The surrounding substrate can influence survival, behavior, and function.

Even in small amounts, a biologically relevant substrate is different from a purely inert filler.

It is also a formulation choice

Raw potato starch also works well as a practical excipient. It has useful manufacturing properties. It is stable in its uncooked form. It is generally well tolerated. Potato allergy exists, but it is uncommon. And unmodified starches are broadly recognized as safe ^[30].

We could have chosen more conventional fillers like maltodextrin or microcrystalline cellulose. We chose a material that also has a clear place in the literature as a prebiotic substrate, especially for the kinds of microbial communities our probiotic strains are intended to complement.

That was not accidental. It was a quiet formulation decision.

What we are not claiming

To keep the boundaries clear:

• We are not claiming that 0.5 grams per day of raw potato starch delivers the same prebiotic effects seen in trials using 3.5 to 40 grams per day.
• We are not claiming glycemic, anti-inflammatory, weight, or metabolic benefits from resistant starch at the dose used in Winnow.
• We are not claiming that the potato starch in Winnow independently reshapes the microbiome.
• We are not positioning potato starch as the main active ingredient in the product. The active ingredients are the probiotic strains.

What we are saying is simpler.

The excipient was chosen with intention. The substrate environment matters. And raw potato starch is a more thoughtful carrier for living organisms than a purely inert space filler.

The synthesis

Resistant starch is one of the best studied prebiotic substrates in the literature. Raw potato starch, specifically in its RS2 form, has physical properties that allow it to survive transit through the upper gut and reach the colon. There, it can help support taxa associated with gut health, including Bifidobacterium, Akkermansia, and Ruminococcus bromii. Its fermentation contributes to butyrate production, which matters for colonocyte energy metabolism, barrier biology, and immune signaling.

At doses of 3.5 grams per day and above, resistant starch has measurable effects in human studies. At Winnow’s dose of approximately 0.5 grams per day, those effects have not been clinically demonstrated, and we think it is important to say that plainly.

The reason this ingredient is in the formula is not because we are trying to borrow claims from higher dose resistant starch trials. It is because we believe the environment a probiotic arrives in matters. We preferred a carrier with real biological relevance over one that merely takes up space. That is not a headline claim. It is a formulation philosophy.

That idea matters even more in a world where microplastic exposure appears to disrupt the gut environment itself. Across the literature, microplastic exposure is often associated with reductions in beneficial bacteria, shifts in fermentation patterns, and signs of barrier stress. That does not mean resistant starch is a complete answer. But it does suggest that, for some people, increasing resistant starch in the diet may be a meaningful way to better support the microbial ecosystem those bacteria depend on.

If the goal is a true dietary dose of resistant starch, the better route is not this capsule alone. It is the broader pattern: cold potatoes, cooked and cooled rice, legumes, green bananas, or additional raw potato starch in gram level amounts. Winnow was not built to replace those strategies. It was built with the same underlying principle in mind: the gut environment matters, and even the quieter ingredients should reflect that.